{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:10:45Z","timestamp":1772820645892,"version":"3.50.1"},"reference-count":52,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T00:00:00Z","timestamp":1433376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0128091","type":"journal-article","created":{"date-parts":[[2015,6,4]],"date-time":"2015-06-04T13:52:42Z","timestamp":1433425962000},"page":"e0128091","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":22,"title":["Projections of the Current and Future Disease Burden of Hepatitis C Virus Infection in Malaysia"],"prefix":"10.1371","volume":"10","author":[{"given":"Scott A.","family":"McDonald","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maznah","family":"Dahlui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosmawati","family":"Mohamed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herlianna","family":"Naning","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatiha Hana","family":"Shabaruddin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adeeba","family":"Kamarulzaman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,6,4]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1478-3231.2008.01934.x","article-title":"The global burden of hepatitis C","volume":"29","author":"D Lavanchy","year":"2009","journal-title":"Liver Int"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: New estimates of age\u2010specific antibody to HCV seroprevalence","volume":"57","author":"KM Hanafiah","year":"2013","journal-title":"Hepatol"},{"key":"ref3","year":"2012"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1177\/0962280208094691","article-title":"An evidence synthesis approach to estimating hepatitis C prevalence in England and Wales","volume":"18","author":"D De Angelis","year":"2009","journal-title":"Stat Meth Med Res"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e1000207","DOI":"10.1371\/journal.pmed.1000207","article-title":"The severity of pandemic H1N1 influenza in the United States, from April to July 2009: a Bayesian analysis","volume":"6","author":"AM Presanis","year":"2009","journal-title":"PLoS Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1186\/s12879-014-0564-6","article-title":"Bridging the data gaps in the epidemiology of hepatitis C virus infection in Malaysia using multi-parameter evidence synthesis","volume":"14","author":"SA McDonald","year":"2014","journal-title":"BMC Inf Dis"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.drugalcdep.2007.05.026","article-title":"Modelling the hepatitis C virus epidemic in Australia","volume":"91","author":"K Razali","year":"2007","journal-title":"Drug Alcohol Depend"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1365-2893.2007.00851.x","article-title":"The burden of hepatitis C in England","volume":"14","author":"MJ Sweeting","year":"2007","journal-title":"J Viral Hepat"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1053\/jlts.2003.50073","article-title":"Projecting future complications of chronic hepatitis C in the United States","volume":"9","author":"GL Davis","year":"2003","journal-title":"Liver Transplant"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1586\/14737167.6.6.627","article-title":"Review of models used to predict the future numbers of individuals with severe hepatitis C disease: therapeutic and cost implications","volume":"6","author":"SJ Hutchinson","year":"2006","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/jvh.12248","article-title":"The present and future disease burden of hepatitis C virus (HCV) infection with today&apos;s treatment paradigm","volume":"21","author":"H Razavi","year":"2014","journal-title":"J Viral Hepat"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jhep.2003.10.018","article-title":"Comparing the public health burden of chronic hepatitis C and HIV infection in France","volume":"40","author":"S Deuffic-Burban","year":"2004","journal-title":"J Hepatol"},{"key":"ref13","year":"2014"},{"key":"ref14","unstructured":"Department of Statistics Malaysia. Population Statistics and Basic Demographic Characteristics Report 2010. <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.statistics.gov.my\/portal\/index.php?option=com_content&id=1215\" xlink:type=\"simple\">http:\/\/www.statistics.gov.my\/portal\/index.php?option=com_content&amp;id=1215<\/ext-link>. Accessed 25 June 2014."},{"key":"ref15","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1365-2893.2006.00785.x","article-title":"Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States","volume":"14","author":"S Deuffic\u2010Burban","year":"2007","journal-title":"J Viral Hepat"},{"key":"ref16","year":"2012"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1080\/09540120802657530","article-title":"The relative risk of HIV among IDUs not in treatment in Malaysia","volume":"21","author":"B Vicknasingam","year":"2009","journal-title":"AIDS Care"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1111\/j.1360-0443.2011.03654.x","article-title":"The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam","volume":"107","author":"A Matser","year":"2012","journal-title":"Addiction"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.jhep.2014.01.020","article-title":"Patient-important benefits of clearing the hepatitis C virus through treatment: A simulation model","volume":"60","author":"H Innes","year":"2014","journal-title":"J Hepatol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2893.2004.00517.x","article-title":"Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection","volume":"11","author":"V Sypsa","year":"2004","journal-title":"J Viral Hepat"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jclinepi.2005.06.008","article-title":"Estimated progression rates in three United Kingdom hepatitis C cohorts differed according to method of recruitment","volume":"59","author":"MJ Sweeting","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/0962280208094690","article-title":"A population-based record-linkage study of mortality in hepatitis C diagnosed persons with and without HIV coinfection in Scotland","volume":"18","author":"SA McDonald","year":"2009","journal-title":"Stat Meth Med Res"},{"key":"ref23","first-page":"429","article-title":"Quantifying the burden of disease: the technical basis for disability-adjusted life years","volume":"72","author":"CJL Murray","year":"1994","journal-title":"Bull World Health Organ"},{"key":"ref24","author":"CJL Murray","year":"1996"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00038-014-0552-z","article-title":"Calculating disability-adjusted life years to quantify burden of disease","volume":"59","author":"B Devleesschauwer","year":"2014","journal-title":"Int J Pub Health"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"e1001205","DOI":"10.1371\/journal.pmed.1001205","article-title":"New methodology for estimating the burden of infectious diseases in Europe","volume":"9","author":"M Kretzschmar","year":"2012","journal-title":"PLoS Med"},{"key":"ref27","author":"ME Stouthard","year":"1997"},{"key":"ref28","unstructured":"World Health Organisation. Global Health Observatory Data Repository [<ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/apps.who.int\/gho\/data\/?theme=main&vid=60990\" xlink:type=\"simple\">http:\/\/apps.who.int\/gho\/data\/?theme=main&amp;vid=60990<\/ext-link>]. Accessed 25 June 2014."},{"key":"ref29","year":"2014"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1002\/sim.3680","article-title":"The BUGS project: Evolution, critique and future directions","volume":"28","author":"D Lunn","year":"2009","journal-title":"Stat Med"},{"key":"ref31","first-page":"12","article-title":"Making BUGS Open","volume":"6","author":"A Thomas","year":"2006","journal-title":"R News"},{"key":"ref32","year":"2007"},{"key":"ref33","year":"2009"},{"key":"ref34","year":"2012"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jhep.2006.05.013","article-title":"The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide","volume":"45","author":"JF Perz","year":"2006","journal-title":"J Hepatol"},{"key":"ref36","year":"2011"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta11110","article-title":"Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: a systematic review and economic evaluation","volume":"11","author":"J Shepherd","year":"2007","journal-title":"Health Tech Assess"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15170","article-title":"Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV\/HIV co-infection: a systematic review and economic evaluation","volume":"15","author":"D Hartwell","year":"2011","journal-title":"Health Tech Assess"},{"key":"ref39","unstructured":"Brady B, Siebert U, Sroczynski G, Murphy G, Husereau D, Sherman M. Clinical and cost-effectiveness of interferon-based therapies for chronic hepatitis C virus infection. Technology Overview no 27. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2007."},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S0140-6736(15)60584-0","article-title":"Hepatitis C: Only a step away from elimination?","volume":"385","author":"The Lancet","year":"2015","journal-title":"Lancet"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/hep.27039","article-title":"Sticker shock and the price of new therapies for hepatitis C: Is it worth it?","volume":"59","author":"NS Reau","year":"2014","journal-title":"Hepatol"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"407","DOI":"10.7326\/M14-1152","article-title":"Cost-effectiveness of novel regimens for the treatment of hepatitis C virus","volume":"162","author":"M Najafzadeh","year":"2015","journal-title":"Ann Intern Med"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Linas BP, Barter DM, Morgan JR, Pho MT, Leff JA, Schackman B, et al. The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med. 2015. <comment>doi: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/dx.doi.org\/10.7326\/M14-1313\" xlink:type=\"simple\">10.7326\/M14-1313<\/ext-link><\/comment>","DOI":"10.7326\/M14-1313"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1093\/ije\/dyg266","article-title":"Commentary: Modelling the epidemiology of hepatitis C and its complications","volume":"32","author":"GL Armstrong","year":"2003","journal-title":"Int J Epidemiol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/QAD.0b013e32830e6d51","article-title":"Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis","volume":"22","author":"HH Thein","year":"2008","journal-title":"AIDS"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/cid\/cit377","article-title":"Elimination of hepatitis C virus infection among people who inject drugs through treatment as prevention: feasibility and future requirements","volume":"57","author":"J Grebely","year":"2013","journal-title":"Clin Inf Dis"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/hep.24656","article-title":"Cost\u2010effectiveness of hepatitis C virus antiviral treatment for injection drug user populations","volume":"55","author":"NK Martin","year":"2012","journal-title":"Hepatol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/jvh.12371","article-title":"Estimates on HCV disease burden worldwide\u2013filling the gaps","volume":"22","author":"H Wedemeyer","year":"2014","journal-title":"J Viral Hepat"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/j.1365-2893.2005.00651.x","article-title":"Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies","volume":"13","author":"JM Micallef","year":"2006","journal-title":"J Viral Hepat"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta10210","article-title":"Health benefits of antiviral therapy for mild chronic hepatitis C: randomised controlled trial and economic evaluation","volume":"10","author":"M Wright","year":"2006","journal-title":"Health Technol Assess"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1002\/hep.20836","article-title":"Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland","volume":"42","author":"SJ Hutchinson","year":"2005","journal-title":"Hepatol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1053\/gast.1997.v112.pm9024300","article-title":"Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients","volume":"112","author":"G Fattovich","year":"1997","journal-title":"Gastroenterol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0128091","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,20]],"date-time":"2018-10-20T05:10:00Z","timestamp":1540012200000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0128091"}},"subtitle":[],"editor":[{"given":"Yury E","family":"Khudyakov","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,6,4]]},"references-count":52,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2015,6,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0128091","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725533917.793507266","asserted-by":"object"}]},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,4]]}}}